Aslan Pharma Selects PharmaNet/i3 as Clinical Trial Partner

Aslan Pharma, the Singapore in-licensing startup, selected PharmaNet/i3 to conduct Phase I and Phase II clinical trials for two of Aslan's cancer drug candidates. PharmaNet/i3, a CRO specializing in clinical-stage studies, is a part of inVentive Health. ChinaBio® Today recently interviewed Carl Firth, PhD, MBA, Aslan’s CEO, who discussed the company’s business plan More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});